Daiwa Securities Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-126
Closed -$13K 1356
2023
Q2
$13K Hold
126
﹤0.01% 1130
2023
Q1
$11K Buy
126
+18
+17% +$1.06K ﹤0.01% 1110
2022
Q4
$4K Hold
108
﹤0.01% 1177
2022
Q3
$3K Hold
108
﹤0.01% 1212
2022
Q2
$3K Hold
108
﹤0.01% 1216
2022
Q1
$4K Hold
108
﹤0.01% 1204
2021
Q4
$3K Hold
108
﹤0.01% 1263
2021
Q3
$11K Buy
108
+46
+74% +$5.39K ﹤0.01% 1133
2021
Q2
$9K Hold
62
﹤0.01% 1049
2021
Q1
$6K Buy
62
+8
+15% +$933 ﹤0.01% 1073
2020
Q4
$7K Sell
54
-106
-66% -$13.9K ﹤0.01% 1038
2020
Q3
$16K Buy
160
+7
+5% +$875 ﹤0.01% 1013
2020
Q2
$22K Hold
153
﹤0.01% 1019
2020
Q1
$22K Hold
153
﹤0.01% 1002
2019
Q4
$31K Hold
153
﹤0.01% 988
2019
Q3
$12K Hold
153
﹤0.01% 1027
2019
Q2
$14K Hold
153
﹤0.01% 1038
2019
Q1
$13K Buy
153
+43
+39% +$3.57K ﹤0.01% 1019
2018
Q4
$6K Hold
110
﹤0.01% 1048
2018
Q3
$9K Hold
110
﹤0.01% 1051
2018
Q2
$4K Hold
110
﹤0.01% 1111
2018
Q1
$2K Buy
+110
New +$2.83K ﹤0.01% 1135
2017
Q2
Sell
-36,611
Closed -$829K 1026
2017
Q1
$829K Buy
+36,611
New +$904K 0.01% 484

Other funds holding RETA

Daiwa Securities Group's RETA Position: Q3 2023 in Review

Daiwa Securities Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 126 shares — an estimated $13K sold.

Daiwa Securities Group first reported a position in RETA in Q1 2017 and held it in 23 quarters. The position peaked at $829K in Q1 2017. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Daiwa Securities Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 126 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $13K.
  • Daiwa Securities Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 23 quarters.
  • Daiwa Securities Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $829K in Q1 2017.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Daiwa Securities Group's 13F filing for Q3 2023, filed 1 Nov 2023.